The Life Sciences and Public M&A teams guided SpringWorks Therapeutics (Nasdaq: SWTX) in the closing of its acquisition by Merck KGaA, Darmstadt, Germany (DAX: MRK), a leading science and technology company, for an equity value of approximately $3.9 billion, following regulatory clearances and the fulfillment of other customary closing conditions.
The definitive agreement between Merck KGaA, Darmstadt, Germany and SpringWorks was announced on 28 April, 2025. It represents one of the biggest M&A deals in the global biopharma sector so far in 2025.
SpringWorks is a commercial-stage biopharmaceutical company dedicated to improving the lives of patients with severe rare diseases and cancer. The company develops and is commercializing OGSIVEO® (nirogacestat) as the first and only FDA-approved medicine for adults with desmoid tumors and GOMEKLI™ (mirdametinib) as the first and only FDA-approved medicine for both adults and children with neurofibromatosis type 1 associated plexiform neurofibromas (NF1-PN).
The Goodwin team was led by Stuart Cable, Robert Masella, Mike Patrone, Jean Lee, and Amanda Gill and included Kingsley Taft, Lisa Haddad, Sarah Ashfaq, Nathalie Dabrowski, Andrew Yu, Alice Choi, Claire Treesh, Sean Philbin, Kelvin Tsz Ho Chan, Alexandra Denniston, Dr. Markus Käpplinger, Robert Jochim, Arman Oruc, Brady Cummins, Simone Waterbury, Anuj Ghai, Julie Tibbets, Elizabeth Mulkey, Tim Worden, Lucy Sharples, Dan Karelitz, Jacob Osborn, Heath Ingram, Christopher Denn, Jennifer Fay, Jackie Klosek, Deborah Birnbach, Jennifer Luz, Christina Ademola and Brian Mukherjee.
For more information on the deal, please see the press release.